TYLER MATHISEN, NIGHTLY BUSINESS REPORT ANCHOR: Stunning setback.
The House torpedoes a key trade-related bill, an essential step to granting the president negotiating power. But the fight is far from over.
SHARON EPPERSON, NIGHTLY BUSINESS REPORT ANCHOR: Triple digit decline. Stocks end the week with a sharp slide, and there are three things that could do that even more next week.
MATHISEN: Drowning in debt. A surprising number of homeowners still owe more on their mortgages than their homes are worth, even as home values rise across the country.
All that and more tonight on NIGHTLY BUSINESS REPORT for Friday, June 12th.
EPPERSON: Good evening, everyone. I`m Sharon Epperson, in tonight for Sue Herera.
MATHISEN: And good evening from me as well. Thanks for joining us.
I`m Tyler Mathisen.
A triple digit decline on Wall Street. More on that in a moment.
But we begin with a big defeat for the White House, the key bill related to the president`s push to be granted expanded trade negotiating authority has been rejected by the House and his own party. A last-minute trip to Capitol Hill to deliver a personal plea to fellow Democrats wasn`t enough.
In the end, the vote was an astonishing 302-126 on a portion of the package of legislation to helps workers who lose their jobs because of imports. That leaves the president`s fast-track authority in limbo, which would give the administration the ability to wrap up negotiations on the transpacific partner, a massive free trade deal, affecting 40 percent of the global economy.
John Harwood tells us what happened today and what`s next.
JOHN HARWOOD, NIGHTLY BUSINESS REPORT CORRESPONDENT: This was a very big defeat for President Obama and Republican leaders in the House and Senate. They needed this package to go through as a whole in order to advance the president`s trade agenda and clear away from the T transpacific trade partnership deal that they hoped to negotiate with a dozen nations later this year and conclude and get it enacted into law.
The rebellion by Democrats sunk the portion of the package that was meant to sweeten the pot for Democrats, that is trade adjustment assistance. Now that has gone down, TPA itself got a majority. If Republicans are able to bring the trade adjustment assistance back for another vote, they can, in fact, move forward, but it`s going to require another vote or changing that package and getting the Senate to pass as well, which is more difficult.
The more likely thing to happen is that the House is going to try another vote, perhaps next week, and see if they can wrangle enough Republicans to vote for this program that was first initiated by labor unions and get that to be the union for the free trade deal that they want and President Obama wants.
For NIGHTLY BUSINESS REPORT, I`m John Harwood in Washington.
MATHISEN: Well, the White House called today`s trade vote a, quote, “procedural snafu” and said it`s important for Republicans and Democrats to come together on that trade adjustment assistance.
EPPERSON: It is clear that the debate over trade is far from over.
Hampton Pearson takes a look at who is on either side of this controversial piece of legislation and what they have at stake.
HAMPTON PEARSON, NIGHTLY BUSINESS REPORT CORRESPONDENT (voice-over):
Today was a big win for big labor. Organized union leaders say they are focused in the millions of manufacturing jobs lost over the last decade to China and other low wage economies was a key factor in Congress stalling key legislation tied to the Trans Pacific Partnership.
ERIC HAUSER, AFL-CIO: This is the beginning of a new look at our economy. That there is a clear choice that was made today between workers and their rights and their needs and their family and community and a sense of corporate entitlement around the country.
PEARSON: When the votes were counted, the worker subsidy measure was defeated overwhelmingly, a rare vote by the Republican majority against big business.
UNIDENTIFIED MALE: The ayes are 126, the nays are 302. The motion is not adopted.
PEARSON: The 12-nation Trans Pacific Partnership would encompass 40 percent of the global economy and about one-third of all of the global trade. The biggest upside for the American economy, a chance to open up Asian markets to American agriculture, the pharmaceutical industry, as well as high-tech and a knowledge-based economy, where U.S. companies have a strong competitive advantage — all part of a bottom line to overall U.S.
STEVE CASE, AOL (NYSE:AOL) CO-FOUNDER: We live in a global economy and recognize that and need to make sure we remain as innovative and entrepreneurial as we can as a nation, but sort of a global marketplace and breakdown some of those barriers, break down those walls, and trade is part of that.
PEARSON (on camera): The House did vote to green light the authority for the president to negotiate what could be the biggest regional trade deal in American history.
In the meantime, both big business and labor are now digging in for a battle that is far from over.
For NIGHTLY BUSINESS REPORT, I`m Hampton Pearson in Washington.
MATHISEN: On Wall Street, a triple digit decline on blue chip Dow index as concerns over Greece continue to weigh on stocks. By the close of trading today, the Dow Jones Industrial Average fell 140 points to 17,898, back below 18. The NASDAQ dropped 31 and the S&P 500 lost 14 points.
Despite today`s big move, all three of those indexes barely budged for the week to moving up a little, the NASDAQ lower. Next week could be different.
Bob Pisani of the New York Stock Exchange has the three things investors like you need to watch.
BOB PISANI, NIGHTLY BUSINESS REPORT CORRESPONDENT: Investors escape with little damage this week but things may get more volatile next week.
Here`s three events that may move stocks:
First and more important, the Federal Reserve can lose its two-day meeting on Wednesday. No one is expected to raise rates at this meeting or really even in July but most are expecting them to lay the groundwork for a September rate hike. The trick would be to do that without causing a sudden spike in interest rates. Many believe the Fed will likely announce a one and done policy, where they raise rates once in September and then hold off for the rest of the year.
Second, we get housing starts on Tuesday. They hit a seven-year high in April, and we`ll likely be below that for May, but anything close to that will enforce the idea that the housing market has recovered from its spring slump.
Finally, next Friday is a quadruple day, the quarterly expiration of stock and index options, and stock and index futures. Despite concerns about rate hikes, traders have not yet panicked and they sought to buy protection from market volatility. Not yet, but the Fed meeting may make them change their minds.
For NIGHTLY BUSINESS REPORT, I`m Bob Pisani at the New York Stock Exchange.
EPPERSON: Our guest tonight says there`s something else investors should be watching next week that could drive trading during the entire second quarter. He`s Jeff Kleintop, chief global investment strategist at Charles Schwab.
Jeff, thanks for being here.
JEFFREY KLEINTOP, CHARLES SCHWAB CHIEF GLOBAL INVESTMENT STRATEGIST:
EPPERSON: What is the big thing? Does this have to do with preannouncement?
KLEINTOP: It does. You know, we`re headed into the last couple of weeks to the quarter here, and that often is confession season as companies confess maybe what might be dragging down the results during the quarter.
The good news is, though, it looks like a lot of the big drags on first-quarter earnings faded in the second quarter. We`re not seeing the same moves in the dollar or oil, the same weather effects or west coast port strike. That could be the results for Q2 could be better than what may be Q1 guidance look like when they last spoke to us.
MATHISEN: Are there any particular companies or sectors that we ought to be on special watch for?
KLEINTOP: Well, we definitely want to watch some of the multinationals, particularly in the industry and technology areas who are exporting a lot, perhaps into Europe as we look at those economies beginning to recover here in the second quarter and also the movements in the dollar certainly acting as maybe a negative to some of these companies but most likely with the economic recovery, maybe seeing themselves pick up. There`s a balance between those two factors, something we want to watch closely.
EPPERSON: What about looking overseas? Should we be concerned about Greece as we always seem to be? Or is there anything to pay close attention to?
KLEINTOP: You know, Greece is certainly something to watch and creates volatility. Overseas, another factor might be the MERS outbreak in South Korea and other places in the Asian region that`s weighing on those indices and certainly weighing on the airline stocks as well, as those outbreaks continue.
But it looks like they may have this contained now and if that seems to be the case over the next few weeks, you might see a rebound in some of those indices.
EPPERSON: And I know you`ll be watching the Fed as well as all investors will be next week.
Jeff Kleintop with Charles Schwab, thanks for joining us.
KLEINTOP: Thank you.
MATHISEN: Consumers are feeling better about the economy, it appears, according to the University of Michigan survey. Sentiment rebounded in early June, and beat expectations. The rise comes despite higher gasoline prices. That jump caused so-called producer prices to record their biggest increase since 2012. The producer price index which measures the wholesale prices that businesses get for goods and services increased 0.5 percent last month.
EPPERSON: Another key pillar of the economy, housing. As home prices rise, more and more borrowers are coming up from their being underwater on their mortgages. They`re finally regaining the home equity they lost during the crash. But the problem is far from over and it is one of the reasons there are so few homes available to buy today.
Diana Olick reports.
DIANA OLICK, NIGHTLY BUSINESS REPORT CORRESPONDENT (voice-over):
David and Heather Littlejohn just loved building their rural Oregon home back in 2005. But even then, they considered it a starter home. When we talked to them two years ago, they were deeply underwater on their mortgage but hopeful they could dig their way out.
Today, with their third Littlejohn knocking at the door, they are still stuck. We caught up with them on Skype.
HEATHER LITTLEJOHN, UNDERWATER BORROWER: I did not expect to be here.
Our original plan was three to five years in this home and we have since converted Dave`s office to a nursery which we figure, you know, will help us get through the next couple of years. But we`re still hoping to move.
OLICK: Nearly 8 million borrowers are still underwater. That`s a little more than 15 percent with a home mortgage, according to Zillow. A vast improvement over last year but still about half of those borrowers are deeply under water, owing at least 20 percent more on the loans than the current value of their home.
(on camera): With home price gains expected to moderate, these borrowers could remain underwater for many years to come. And that throws a real wrench into the housing cycle, especially when it comes to starter homes like the Littlejohn.
STAN HUMPHRIES, ZILLOW CHIEF ECONOMIST: Those are the homes that attract first-time home buyers and because so many homeowners are underwater in that segment of the housing stock, it makes it hard for them to sell their home to new buyers, which makes it hard for them to move up and supply the demand to the people on the next rung of the ladder.
DAVID LITTLEJOHN, UNDERWATER BORROWER: There`s great bargains that we`d like to move into, but it is still, since we really haven`t developed any equity in our own situation, we`re going to have to produce the equity in some other fashion.
OLICK (voice-over): While their home has appreciated, they were so far under that coming up could take several more years. In the meantime, the Littlejohns are aggressively saving and considering paying into the mortgage in order to get out of the house.
For NIGHTLY BUSINESS REPORT, I`m Diana Olick in Washington.
MATHISEN: Still ahead, our market monitor says, forget stocks.
Investors should own mutual funds instead and he`ll tell us which ones he likes right now.
EPPERSON: There may be another showdown in Congress. As we told you yesterday, the Export-Import Bank`s charter expires at the end of the month. And that`s a big deal to big business. The Export-Import Bank benefits big American businesses like Boeing (NYSE:BA) and Caterpillar
(NYSE:CAT) by extending loan guarantees to foreign customers, who are buying American exports. But it also benefits many customers in the Gulf region.
Hadley Gamble explains.
HADLEY GAMBLE, NIGHTLY BUSINESS REPORT CORRESPONDENT (voice-over):
They are among the wealthiest countries in the world. And when it comes to doing business, they aren`t above hunting for a bargain. With a population set to skyrocket over 40 percent in the coming decades, the economic forum predicts the Middle East and North Africa will need to invest over a year in infrastructure just to keep up.
And that`s good news or could be for some of America`s biggest private employers. Companies in Saudi Arabia, the UAE and Turkey top the list of beneficiaries of the controversial U.S. Export-Import Bank. Data shows U.S. taxpayer money has helped subsidize the purchase of everything from nuclear reactors to commercial aircraft, with a Near East and North Africa accounting for as much as 13 percent of the total XM trade financing between 2010 and 2014.
Now as the 80-year-old program gets set to expire, critics are amping up the rhetoric, claiming that the multibillion dollar profit for U.S.
companies like Boeing (NYSE:BA) and G.E. don`t necessarily mean bigger benefits for employees or taxpayers.
But with billions of dollars in regional mega projects up for grabs, supporters say it will be a shame for U.S. companies to miss out on the action.
For NIGHTLY BUSINESS REPORT in London, I`m Hadley Gamble.
MATHISEN: Wall Street had a big appetite for the chicken wing chain Wing Stop and that`s where we begin tonight`s “Market Focus”. I`m hungry.
The Dallas-based restaurant surged in its trading debut, valuing the company at nearly $1 billion. Shares were priced at $19 a piece and all the wings you can eat. The stock closed at $30.59. That was an increase of 61 percent on the day.
FedEx (NYSE:FDX) will book a pre-tax charge of more than $2 billion.
This is a result of the shipping company`s decision to switch to a pension accounting method that it says will make it easier to gauge plan performance. Shares at FedEx (NYSE:FDX) off a fraction today to $183.63.
EPPERSON: And, Tyler, there is more on Twitter CEO shakeup. Incoming CEO and co-founder Jack Dorsey spoke today about the abrupt departure of Dick Costolo.
(BEGIN VIDEO CLIP)
JACK DORSEY, INCOMING INTERIM CEO, TWITTER: We always had an open conversation with Dick and the leadership and the board about the next step of the company and we do that just in service of making sure that we`re putting the company first. We did not want to interrupt the momentum. If anything, we want to amplify it, because we`re extremely excited about the products and new initiatives to come.
(END VIDEO CLIP)
EPPERSON: And even on those comments, shares were just a few cents higher at $35.90.
Bob Evans is considering either converting to a real estate investment trust otherwise known as a REIT, or selling and than leasing back its restaurant properties. The restaurant chain and food distributor will make a decision within the next few months. Shares were up almost 3 percent on the news to $47.41.
MATHISEN: Big week, Sharon, for shares for Eli Lilly (NYSE:LLY). The stock gain more than 7 percent, despite today`s pull back. Big move in a short period of time for a big pharmaceutical company. There you see it.
And many say it has to do with Lilly`s experimental Alzheimer`s drug.
Meg Tirrell has more.
MEG TIRRELL, NIGHTLY BUSINESS REPORT CORRESPONDENT (voice-over):
Alzheimer`s disease has been a particularly challenging area for the pharmaceutical industry, with drugs failing in the late stages of clinical trials. There are no medicines on the market that target the underlying cause of the disease, which affects more than 5 million Americans. So, excitement has been increasing around experimental drugs that have shown some promise in studies.
Eli Lilly`s Solanezumab is one of them and it`s already experience some failure itself.
DAMIEN CONOVER, MORNINGSTAR: It had what I would say is a checkered past. It had two phase three studies, both of which failed to hit their primary end points.
TIRRELL: Despite the setback in 2012, Lilly said it identified a group of patients for whom the drug appeared to be working.
CONOVER: They considered to be considered a little bit more mild to moderate Alzheimer`s patients. These patients appear to be responding a little bit better than patients who have had the disease for a long period of time.
TIRRELL: The Indianapolis-based drugmaker is now focusing on that patient group and clinical trials. Its key study expected to report results late next year, but it could provide some updates on how it`s doing ahead of an Alzheimer`s conference in July.
The excitement around Lilly`s drug follows a run-up earlier this year for computer Biogen, which showed some promising data on a similar medicine. They both target the amyloid plaques in the brain associated with Alzheimer`s disease, unlike currently approved medicines that target only the symptoms, with limited effects.
That enthusiasm for new Alzheimer`s drugs helps drive newly public biotech company Axovant shares to almost double yesterday in their first day of trading. The company now has a market value of almost $3 billion.
(on camera): Morningstar (NASDAQ:MORN) analyst Damien Conover estimates Lilly`s drug, if successful, could draw more than $2 billion in annual revenue, likely priced at more than $10,000 a year. But it will have to get through the last stages of testing first and may not hit the market until late 2017.
He warns the movement in Lilly stock price may reflect too much optimism that risky pipeline products like Solanezumab and another medicine for cholesterol called Evacetrapib will work.
CONOVER: Both Solanezumab and Evacetrapib are a little bit more on the risky side, you know, swing for the fences products and a lot of times when you swing for the fences, you strike out.
TIRRELL: With Alzheimer`s cases expected to triple by 2050 without new treatment, patients, families and investors are all hoping for a hit.
For NIGHTLY BUSINESS REPORT, I`m Meg Tirrell.
EPPERSON: Eleven percent of American children ages four to 17 have attention deficit disorder, according to the Centers for Disease Control.
Billions of dollars are spent each year on drugs to treat the disorder.
But one startup says it can help people in a way that replaces the need for medication.
Dina Gusovsky has our story.
AZIZ KADDAN, MYNDLIFT: Go ahead and put it in your hand. This should go behind your ears.
DINA GUSOVSKY, NIGHTLY BUSINESS REPORT CORRESPONDENT: Am I the red guy or purple guy?
KADDAN: You`re the purple guy.
GUSOVSKY (voice-over): This is not your typical mobile gaming device, because Myndlift created by an Arab-Israeli entrepreneur is meant to help people with attention deficit hyper activity disorder, known as ADHD.
Exercises like this could help improve concentration levels.
KADDAN: So, the point of this is, the more you concentrate, the higher it will jump. So, we have a video exercise if which you will see a movie that is controlled by your concentration levels.
GUSOVSKY: The more you concentrate, the brighter the screen becomes.
Same with volume here.
KADDAN: So, this shows the progress of the user.
GUSOVSKY (on camera): What inspired you to do this?
KADDAN: Both my sister and brother have been diagnosed with ADHD and they started taking ADHD medication which had me witnessing the most annoying side effects starting from headaches, lack of sleep, loss of appetite.
GUSOVSKY (voice-over): Even with the potential side effects associated with ADHD medications, it`s a multibillion dollar market for drug makers.
KADDAN: You know, the neuro feedback is an amazing technique that can deal with ADHD.
GUSOVSKY: Neuro feedback, that`s what tracks brainwaves, which were then sent to this software to monitor concentration levels. But there are skeptics about how far the company could actually go.
DAVID STEINBERG, JEFFERIES SENIOR RESEARCHER ANALYST: It sounds like a very exciting technology, but there`s not a lot of information available.
No parent wants to give their child a medication. However, there are limitations to behavioral modification at present.
GUSOVSKY: Still, this entrepreneur hopes this device will train people to focus without taking medicine.
KADDAN: We gather a team of designers, software engineers and people who have come from the medical field in order to create this.
GUSOVSKY: For NIGHTLY BUSINESS REPORT, I`m Dina Gusovsky in New York.
MATHISEN: Tonight`s market monitor says, buy the manager, not the fund. In fact, he trademarked that statement. Last time he was on with us, his picks were Apple (NASDAQ:AAPL), it`s up 19 percent since then, UPS down 3 percent, and Visa (NYSE:V) up 17 percent. Let`s hope he does as well this week.
He`s Jim Lowell, chief investment officer at Adviser Investments.
Let`s start with a quick thought on what you see for the markets over the next six months.
JIM LOWELL, ADVISER INVESTMENTS CHIEF INVESTMENT OFFICER: I think we`re going to see a lot of near term volatility, Greece or otherwise. We know that this is a market that`s prone to whatever our Fed may or may not do, and all the rumors that attend to it. So, I think investors are going to have to get used to a lot more volatility, if not just market volatility, emotional volatility, as well, let into that mix, games typically are made, especially if you`re a good, long-term investor, or invest in long-term investing.
EPPERSON: Are there certain mutual funds that you could invest in that will help to alleviate some of that volatility? What are some of your favorites right now?
LOWELL: So, I`d say my hat trick of picks for hopefully a trinity of gains would be Fidelity Mega Cap stock, Fidelity International Growth and Fidelity Japan Smaller Companies. I don`t own the investor Fidelity Funds but I like those three in particular. The managers behind each of them has stellar track records not just in up markets, but also defending well against downdrafts, losing less will enable each of those measures I think to be able to climb out of a shallower hole versus an index fund or an ETF.
In particular, I like the U.S. Mega Cap space because it`s still relatively undervalued, especially compared do our mid- and small cap areas here at home in large measure due to the fact that their revenues arrived from the international markets which are weaker than our own.
And across the pond, Europe is just a perfect trouble spot. There`s a tempest of almost every teapot there. That`s great news for a manager like Jed Weiss of International Growth, that`s got a long-term track record of going in, turning over the stones, finding the rubies in the rubble.
And Japan Smaller Companies basically helps me sidestep the Nikkei 225, Japan`s equivalent to our S&P 500, which sets successive 15-year highs almost every week. I think that`s overvalued. But in the mid and small cap camp, they`re not vulnerable to currency and exports, and if you know what you are doing, there are over 1,000 companies in the Japan marketplace with P/Es under 13. They`re less than 200 in our own Russell 2000.
MATHISEN: Jim, I`ve known your work for a long time. I just want to be absolutely clear with the viewers — you specialize or at least these picks are Fidelity picks. You have a newsletter that is independent of Fidelity Adviser or something like that. Just to be clear.
LOWELL: It`s called Fidelity Investor.
LOWELL: Yes, it`s called Fidelity Investor, and it`s been out and about for over 15 years, top-ranked by Mark Hulbert, and it`s also completely independent from Adviser Investments. But that is one of my expertises. I also have been writing about exchange traded funds since 1996, a long time before anybody even thought they were the best mousetrap in town.
All right. Jim, thank you very much. We appreciate it and appreciate your time this week. Have a great weekend.
LOWELL: Thank you. You too.
EPPERSON: Coming up, despite generating billions in revenue, one industry is having a hard time finding a bank to do business with. That story, next.
EPPERSON: There may have been second government data breach. “The Associated Press” is reporting that hackers linked to China gained access to sensitive background information submitted by intelligence and military personnel seeking security clearances.
MATHISEN: Well, entrepreneurs are launching legal marijuana businesses at record rates in many states. But like any growing industry, the pot business is seeing its share of growing pains. And one of the biggest hurdles is finding a bank to do business with.
Kate Rogers (NYSE:ROG) talks to one entrepreneur who`s trying to overcome that challenge.
KATE ROGERS, NIGHTLY BUSINESS REPORT CORRESPONDENT (voice-over):
Despite continued progress in the fight to legalize marijuana for both medicinal and recreational use, the drug is still illegal on a federal level. This means entrepreneurs looking to cash in on the budding business model struggle to establish relationships with the banking community.
It`s a battle Andrew DeAngelo knows too well.
ANDREW DEANGELO, HARBORSIDE HEALTH CENTER: If you`ve gone through five, 10, 15, 20 banks, we`re on our 15th bank or so right now. Once you go through that experience that many times, you sort of learn how to improve the way in which you establish these relationships with banks.
ROGERS: DeAngelo and his brother run Harborside Health Center, a medicinal marijuana dispensary collective in Oakland, California. They`ve been in business for nearly a decade. In that time, they managed to form two relationships wit banks, one a credit union and the other a regional.
But he knows that at any minute, those partnerships may disappear.
DEANGELO: Instead of going through the trouble of establishing a legitimate paper trail for their clients in the cannabis sector, they`ll just not do business with anybody in the sector because it`s just easier for them.
ROGERS (on camera): The team here at Harborside deals with a lot of cannabis and cash. In fact, I`m holding nearly three pounds of marijuana here, which is worth about $9,000. But one of the things that makes Harborside a standout in this community, they have employed a ton of best practices, which would allow them to establish a working relationship with the banking community.
Things as simple as properly counting cash go a long way with establishing trust with banks.
DEANGELO: It`s really about watching and counting over and over again and making sure that people — when there are shortages, if they are shortages, we do a through investigation.
ROGERS (voice-over): Harborside has an extensive security measures with vaults upon vaults. They have more than 40 cameras angles and biometric finger scanner on doors behind the scene.
But even with these measures, DeAngelo knows that his banking relationships are fragile, subject to change with cultural and political shifts.
For NIGHTLY BUSINESS REPORT in Oakland, California, I`m Kate Rogers (NYSE:ROG).
EPPERSON: And that`s NIGHTLY BUSINESS REPORT for tonight, I`m Sharon Epperson. Thanks so much for watching.
MATHISEN: And I`m Tyler Mathisen. Thanks from me as well. We hope to see you right back here on Monday.
Nightly Business Report transcripts and video are available on-line post broadcast at http://nbr.com. The program is transcribed by CQRC Transcriptions, LLC. Updates may be posted at a later date. The views of our guests and commentators are their own and do not necessarily represent the views of Nightly Business Report, or CNBC, Inc. Information presented on Nightly Business Report is not and should not be considered as investment advice. (c) 2015 CNBC, Inc.